Diabetes 53:2051-2059, 2004
© 2004 by the American Diabetes Association, Inc.
Splanchnic Cortisol Production Occurs in Humans
Evidence for Conversion of Cortisone to Cortisol Via the 11-ß Hydroxysteroid Dehydrogenase (11ß-HSD) Type 1 Pathway
Rita Basu1,
Ravinder J. Singh2,
Ananda Basu1,
Elizabeth G. Chittilapilly1,
C. Michael Johnson3,
Gianna Toffolo4,
Claudio Cobelli4, and
Robert A. Rizza1
1 Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota
2 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
3 Department of Vascular and Interventional Radiology, Mayo Clinic, Rochester, Minnesota
4 Department of Information Engineering, University of Padua, Padua, Italy
Glucocorticoids are potent regulators of protein, fat, and carbohydrate metabolism. To determine if cortisol production occurs within the splanchnic bed in humans, 11 nondiabetic subjects were studied using the hepatic/leg catheterization method along with an infusion of [9,11,12,12-2H4] cortisol (D4-cortisol) as proposed by Andrews et al. In the fasting state, there was net release (P < 0.05) of cortisol from the splanchnic bed (6.1 ± 2.6 µg/min) and net uptake (P < 0.05) by the leg (1.7 ± 0.7 µg/min). This, along with cortisol production by other tissues (e.g., the adrenals), resulted in a total-body cortisol appearance rate of 18.1 ± 1.9 µg/min. Fractional splanchnic D4-cortisol extraction averaged 12.9 ± 1.3% (P < 0.001), splanchnic cortisol uptake 14.8 ± 2.0 µg/min (P < 0.001), and splanchnic cortisol production 22.2 ± 3.3 µg/min (P < 0.001). On the other hand, fractional leg D4-cortisol extraction averaged 5.6 ± 1.8% (P < 0.02), leg cortisol uptake 2.3 ± 0.7 µg/min (P < 0.01), and leg cortisol production 0.4 ± 0.4 µg/min, which did not differ from zero. Because D4-cortisol loses a deuterium during conversion to [9,12,12-2H3] cortisone (D3-cortisone), which in turn generates [9,12,122H3] cortisol (D3-cortisol) via 11-ß hydroxysteroid dehydrogenase (11ß-HSD) type 1, D3-cortisol production can be used as an index of 11ß-HSD type 1 activity. Net splanchnic D3-cortisol release (3.9 ± 0.4 µg/min) and splanchnic D3-cortisol production (7.1 ± 0.7 µg/min) occurred (P < 0.01) in all subjects. In contrast, there was minimal leg D3-cortisol production (0.04 ± 0.01 µg/min), resulting in a strong correlation between splanchnic D3-cortisol production and total-body 3D-cortisol production in both the fasting state (r = 0.84; P < 0.02) and during an infusion of insulin (r = 0.97; P < 0.01). Thus, splanchnic production of cortisol occurs in nondiabetic humans at rates approximating that which occurs in the remainder of the body. These data support the possibility that alterations in splanchnic cortisol production contribute to visceral fat accumulation and the hepatic insulin resistance of obesity or type 2 diabetes.
Address correspondence and reprint requests to Robert A. Rizza, MD, Mayo Clinic, 200 1st St. SW, Rm. 5-194 Joseph, Rochester, MN 55905. E-mail: rizza.robert{at}mayo.edu

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Jang, V. R. Obeyesekere, R. J. Dilley, Z. Krozowski, W. J. Inder, and F. P. Alford
Altered Activity of 11{beta}-Hydroxysteroid Dehydrogenase Types 1 and 2 in Skeletal Muscle Confers Metabolic Protection in Subjects with Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
August 1, 2007;
92(8):
3314 - 3320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Basu, U. B. Pajvani, R. A. Rizza, and P. E. Scherer
Selective Downregulation of the High Molecular Weight Form of Adiponectin in Hyperinsulinemia and in Type 2 Diabetes: Differential Regulation From Nondiabetic Subjects
Diabetes,
August 1, 2007;
56(8):
2174 - 2177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Wake, R. H. Stimson, G. D. Tan, N. Z. M. Homer, R. Andrew, F. Karpe, and B. R. Walker
Effects of Peroxisome Proliferator-Activated Receptor-{alpha} and -{gamma} Agonists on 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Subcutaneous Adipose Tissue in Men
J. Clin. Endocrinol. Metab.,
May 1, 2007;
92(5):
1848 - 1856.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R WALKER and R. ANDREW
Tissue Production of Cortisol by 11beta-Hydroxysteroid Dehydrogenase Type 1 and Metabolic Disease
Ann. N.Y. Acad. Sci.,
November 1, 2006;
1083(1):
165 - 184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Wake, N. Z. M. Homer, R. Andrew, and B. R. Walker
Acute In Vivo Regulation of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity by Insulin and Intralipid Infusions in Humans
J. Clin. Endocrinol. Metab.,
November 1, 2006;
91(11):
4682 - 4688.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Basu, D. S. Edgerton, R. J. Singh, A. Cherrington, and R. A. Rizza
Splanchnic Cortisol Production in Dogs Occurs Primarily in the Liver: Evidence for Substantial Hepatic Specific 11{beta} Hydroxysteroid Dehydrogenase Type 1 Activity
Diabetes,
November 1, 2006;
55(11):
3013 - 3019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Darmon, F. Dadoun, S. Boullu-Ciocca, M. Grino, M.-C. Alessi, and A. Dutour
Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity
Am J Physiol Endocrinol Metab,
November 1, 2006;
291(5):
E995 - E1002.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Basu, R. Singh, A. Basu, C.M. Johnson, and R. A. Rizza
Effect of Nutrient Ingestion on Total-Body and Splanchnic Cortisol Production in Humans
Diabetes,
March 1, 2006;
55(3):
667 - 674.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Jacobson, T. W. von Geldern, L. Ohman, M. Osterland, J. Wang, B. Zinker, D. Wilcox, P. T. Nguyen, A. Mika, S. Fung, et al.
Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes
J. Pharmacol. Exp. Ther.,
July 1, 2005;
314(1):
191 - 200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Basu, R. J. Singh, A. Basu, E. G. Chittilapilly, M. C. Johnson, G. Toffolo, C. Cobelli, and R. A. Rizza
Obesity and Type 2 Diabetes Do Not Alter Splanchnic Cortisol Production in Humans
J. Clin. Endocrinol. Metab.,
July 1, 2005;
90(7):
3919 - 3926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Basu, V. Chandramouli, B. Dicke, B. Landau, and R. Rizza
Obesity and Type 2 Diabetes Impair Insulin-Induced Suppression of Glycogenolysis as Well as Gluconeogenesis
Diabetes,
July 1, 2005;
54(7):
1942 - 1948.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Andrew, J. Westerbacka, J. Wahren, H. Yki-Jarvinen, and B. R. Walker
The Contribution of Visceral Adipose Tissue to Splanchnic Cortisol Production in Healthy Humans
Diabetes,
May 1, 2005;
54(5):
1364 - 1370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Sandeep, R. Andrew, N. Z.M. Homer, R. C. Andrews, K. Smith, and B. R. Walker
Increased In Vivo Regeneration of Cortisol in Adipose Tissue in Human Obesity and Effects of the 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Carbenoxolone
Diabetes,
March 1, 2005;
54(3):
872 - 879.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Diabetes Association.
|
|
| |
|